LOS ANGELES, Oct. 03, 2023 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”), today announced presentation of additional AL Amyloidosis clinical data from its Phase 1b/2a NEXICART-1 (NCT04720313) study of novel, autologous, BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy, NXC-201, at an oral presentation at the 20th International Myeloma Society Annual (IMS) Meeting being held in Athens, Greece on September 27-30 2023. One new patient and additional follow-up data from an additional 8 patients (9 total) are included in this update. All patients were DARZALEX ® (daratumumab) combination therapy relapsed/refractory and experienced a median of 6 earlier treatments that failed to stop worsening of disease (lines of therapy) prior to receiving NXC-201.

PALO ALTO, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, provides notice to all record holders and beneficial owners of restricted shares of Scilex common stock that were part of the previously announced dividend of Scilex common stock then-held by Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”) to Sorrento equity holders of record as of January 9, 2023.

LOS ANGELES, Oct. 03, 2023 (GLOBE NEWSWIRE) — NeuroSigma today announced approval of the Monarch eTNS System by Singapore’s Health Sciences Authority (HSA), the national body that regulates medical devices, therapeutics, and other healthcare products. The Monarch external Trigeminal Nerve Stimulation (eTNS) System is indicated for treatment of pediatric attention deficit hyperactivity disorder (ADHD) as a monotherapy for patients ages 7 through 12 years old who are not currently taking prescription ADHD medications.

Begins revenue generation for “Camelina Seed Genetics to Biofuel” platform Begins revenue generation for “Camelina Seed Genetics to Biofuel” platform

Cleared First Three Monotherapy Cohorts with No Dose Limiting Toxicity and No Consistent Pattern of Adverse Events at any Dose Level

WATERTOWN, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the initiation of a Phase 1 study of DISC-3405 (formerly MWTX-003) in healthy volunteers. DISC-3405 is a monoclonal antibody designed to target TMPRSS6 (Transmembrane Serine Protease 6, also known as Matriptase-2) to increase hepcidin and decrease iron.

LYON, France, and CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) — Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that it will present two posters at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting, which is being held October 13-16, 2023 in Vancouver, BC, Canada.

LYON, France et CAMBRIDGE, Massachusetts (États-Unis), 03 oct. 2023 (GLOBE NEWSWIRE) — Amolyt Pharma, société spécialisée dans le développement de peptides thérapeutiques ciblant les maladies endocriniennes rares a annoncé ce jour qu’elle présentera deux posters au congrès annuel 2023 de l’American Society for Bone and Mineral Research (ASBMR), qui se tiendra du 13 au 16 octobre 2023 à Vancouver, en Colombie-Britannique (Canada).

SYDNEY, Australia, Oct. 03, 2023 (GLOBE NEWSWIRE) — Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company or Recce), the Company developing a new class of synthetic anti-infectives, announced today the completion of an entitlement offer to shareholders raising approximately $2.7 million before costs.